Yissum Technology Transfer Company of the Hebrew University
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. is a technology transfer company established in 1964 that focuses on protecting and commercializing the intellectual properties of the Hebrew University. It markets and licenses innovations developed by the university's faculty, staff, and students across diverse fields such as agriculture, life sciences, nanotechnology, and environmental technologies. Yissum has a strong track record, having registered over 10,000 patents and produced more than 130 spin-off companies, including notable names like Mobileye and Collplant. The company engages in strategic collaborations with various global partners and manages several venture capital funds, including those targeting nanotechnology, cleantech, and agro-biotechnology. Yissum is headquartered in Jerusalem and has international cooperation centers in Chicago, Asunción, and Shenzhen.
6 past transactions
Agrinnovate India
Series A in 2015
Agrinnovate India Ltd., established in 2011 under the Companies Act, is a for-profit entity owned by the Department of Agricultural Research & Education (DARE), Ministry of Agriculture, Government of India. The company serves as a bridge between the Indian Council of Agricultural Research (ICAR) and various stakeholders in the agricultural sector, including farmers, public and private firms, research organizations, and educational institutions both nationally and internationally. Its primary goal is to secure, sustain, and promote global agricultural development through intellectual property rights protection and fostering innovation in agricultural research and development.
Avraham Pharmaceuticals
Venture Round in 2014
Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, founded in 2010. The company focuses on the development of innovative products for the treatment and prevention of neurodegenerative disorders. Its lead product candidate, Ladostigil, is designed for mild cognitive impairment and employs a combination of neuroprotective mechanisms, including the reduction of oxidative stress, inhibition of pro-inflammatory cytokines, and modulation of microglial activation. Avraham Pharmaceuticals has raised funding to support clinical trials, including a European Phase II proof-of-concept efficacy trial for Alzheimer's disease, aimed at validating the effectiveness of Ladostigil.
Avraham Pharmaceuticals
Private Equity Round in 2013
Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, founded in 2010. The company focuses on the development of innovative products for the treatment and prevention of neurodegenerative disorders. Its lead product candidate, Ladostigil, is designed for mild cognitive impairment and employs a combination of neuroprotective mechanisms, including the reduction of oxidative stress, inhibition of pro-inflammatory cytokines, and modulation of microglial activation. Avraham Pharmaceuticals has raised funding to support clinical trials, including a European Phase II proof-of-concept efficacy trial for Alzheimer's disease, aimed at validating the effectiveness of Ladostigil.
Avraham Pharmaceuticals
Venture Round in 2011
Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, founded in 2010. The company focuses on the development of innovative products for the treatment and prevention of neurodegenerative disorders. Its lead product candidate, Ladostigil, is designed for mild cognitive impairment and employs a combination of neuroprotective mechanisms, including the reduction of oxidative stress, inhibition of pro-inflammatory cytokines, and modulation of microglial activation. Avraham Pharmaceuticals has raised funding to support clinical trials, including a European Phase II proof-of-concept efficacy trial for Alzheimer's disease, aimed at validating the effectiveness of Ladostigil.
Avraham Pharmaceuticals
Series A in 2010
Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, founded in 2010. The company focuses on the development of innovative products for the treatment and prevention of neurodegenerative disorders. Its lead product candidate, Ladostigil, is designed for mild cognitive impairment and employs a combination of neuroprotective mechanisms, including the reduction of oxidative stress, inhibition of pro-inflammatory cytokines, and modulation of microglial activation. Avraham Pharmaceuticals has raised funding to support clinical trials, including a European Phase II proof-of-concept efficacy trial for Alzheimer's disease, aimed at validating the effectiveness of Ladostigil.
Chiasma
Series B in 2005
Chiasma, Inc. is a late-stage biopharmaceutical company based in Needham, Massachusetts, established in 2001. The company specializes in developing oral medications using its proprietary Transient Permeability Enhancer technology, which allows for the conversion of injectable drugs to oral formulations. This platform not only enhances drug absorption but also enables the exploration of new indications for existing therapies. Chiasma's primary product is MYCAPSSA, an oral formulation of octreotide capsules designed for the treatment of acromegaly, a condition characterized by excessive production of growth hormone. Currently, MYCAPSSA is undergoing Phase III clinical trials in the United States and is also being developed for regulatory approval in the European Union, targeting adult patients with this rare and serious condition.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.